The management of Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) continues to evolve with advancements in targeted therapies, antibody-drug conjugates, and MRD-driven treatment approaches. As patient needs become increasingly complex—particularly in relapsed and refractory settings—ongoing research and real-world experience are vital in refining treatment algorithms and optimizing outcomes across diverse patient profiles. This upcoming scientific session will feature expert insights on contemporary challenges and innovations in ALL and MM care, including post-transplant relapse strategies, dual targeting with ADCs such as Inotuzumab and Blinatumomab, and infection prevention in immunocompromised patients. Renowned global and national faculty— Dr. C.
Ola Landgren, Dr. Jabbour, Dr. Kundan Mishra, Dr. Sameer Melinkeri, Dr.VA Arun, and Dr. Narendra Agarwal —will present…